AtaGenix

Hot search： CD47 │ IL6 │ PD-L1 │ CTLA-4 │ TIGIT
Current Site： Product Center / Recombinant Protein / Drug Targets / Recombinant Human CD52 protein ,C- Fc Tag

Recombinant Human CD52 protein ,C- Fc Tag

  • 1
ATMP00243HU
-
+
futures
Inquiry
  • Product Details
  • Frontier progress
  • How to order
  • Instructions
Summaryicon
English name
Recombinant Human CD52 protein ,C- Fc Tag
Purity
>90% as determined by SDS-PAGE
Endotoxin level
<1.0 EU per μg of the protein as determined by the LAL method.
Construction
A DNA sequence encoding the human CD52(Met1-Ser36) was fused with the C-terminal Fc Tag
Accession #
P31358
Host
Mammalian cells
Species
Homo sapiens (Human)
Predicted Molecular Mass
29.07kDa
Formulation
Supplied as solution form in PBS pH 7.5 or lyophilized from PBS pH 7.5.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability &Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
SDS-PAGE imageicon
    Backgroundicon
    Background
    CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.
    Alternative Names
    CDW52,HE5,CD52,CAMPATH-1 antigen
    References
    Trindade, Thaniyavarn, Townsend, Klasek, Tsveybel, Kennedy, Goldberg, El-Chemaly (2020) Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres Frontiers in immunology 11() 1063
    Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1-3). Side effects of alemtuzumab include bone marrow suppression, infection, and malignancy. Whether alemtuzumab can be safely used in allograft recipients that have an increased propensity for bone marrow suppression due to telomeropathies is unknown. In a retrospective case series, we report outcomes associated with alemtuzumab in three lung allograft recipients with short telomere lengths, comparing endpoints such as leukopenia, transfusion needs, infection, hospitalization and survival to those of 17 patients without known telomeropathies that received alemtuzumab. We show that the use of alemtuzumab in lung transplant recipients with short telomeres is safe, though is associated with an increased incidence of neutropenia, thrombocytopenia and anemia requiring packed red blood cell transfusions. Alemtuzumab appears to be an acceptable advanced immunosuppressive therapy in patients with telomeropathies, though given the design and scope of this study, the actual clinical effect needs further evaluation in larger trials.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.

    AtaGenix
    Copyright © 2024 Lawyer Theme All Rights Reserved
    Site map | Contact us | Join us